Evidence map›Paper›PMID 41625479›Full record

ArticleCancer communications (London, England)2026

The Ly6g

Rui Wang, Xiaoqi Liu, Yixuan Hou, Shanchun Chen, Yongcan Liu, Zexiu Lu, Chao Chang, Die Meng, Jing Chen, Xiaojiang Cui and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rui WangKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Xiaoqi LiuPediatric Research Institute, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, P. R. China.
Yixuan HouExperimental Teaching Center of Basic Medicine Science, Chongqing Medical University, Chongqing 400016, P. R. China.
Shanchun ChenKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Yongcan LiuKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Zexiu LuKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Chao ChangKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Die MengKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Jing ChenKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.
Xiaojiang CuiDepartment of Surgery, Department of Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 91006, USA.
Zhengrong ShiDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P. R. China.
Xueying WanKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.ORCID https://orcid.org/0009-0001-2907-4180
Manran LiuKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P. R. China.

Funding

The Role of FOXCI in Basal-like Breast CancerR01CA151610 · NCI · SAINT JOHN'S CANCER INSTITUTE · PI CUI, XIAOJIANG · 2011 to 2022
$3.8M
Crosslinking-based targeted therapy for triple-negative breast cancerR21CA280458 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CHEN, SHENGXI, CUI, XIAOJIANG · 2023 to 2024
$418k
NCI NIH HHS R01 CA151610NCI NIH HHS R21 CA280458
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, LyBreast NeoplasmsCD8-Positive T-LymphocytesLung NeoplasmsNeutrophilsAnimalsAntimicrobial Cationic PeptidesCathelicidinsCell Line, TumorExtracellular TrapsFemaleHumansMiceMice, KnockoutTumor MicroenvironmentAntigens, LyAntimicrobial Cationic PeptidesCathelicidinsLy6G antigen, mouse

Identifiers

PMID41625479
PMCPMC12857760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.